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Abstract
Objective: To compare the effectiveness of intramuscular olanzapine, 
ziprasidone, haloperidol plus promethazine, haloperidol plus midazolam 
and haloperidol alone as the first medication(s) used to treat patients with 
agitation and aggressive behavior. Method: One hundred fifty patients 
with agitation caused by psychotic or bipolar disorder were randomly 
assigned under double-blind conditions to receive olanzapine, ziprasidone, 
haloperidol plus midazolam, haloperidol plus promethazine or haloperidol 
alone. The Overt Agitation Severity Scale, Overt Aggression Scale and 
Ramsay Sedation Scale were applied within 12 hours after the first dosage. 
Results:  All medications produced a calming effect within one hour of 
administration, but only olanzapine and haloperidol reduced agitation by 
less than 10 points, and only olanzapine reduced aggression by less than 
four points in the first hour. After twelve hours, only patients treated with 
haloperidol plus midazolam had high levels of agitation and aggression 
and also more side effects. Ziprasidone, olanzapine and haloperidol 
alone had more stable results for agitation control, while ziprasidone, 
haloperidol plus promethazine and olanzapine had stable results for 
aggression control. Conclusion: Olanzapine, ziprasidone, haloperidol 
plus promethazine, haloperidol plus midazolam and haloperidol were 
effective in controlling agitation and aggression caused by mental illness 
over 12 hours. Although all the drugs had advantages and disadvantages, 
haloperidol plus midazolam was associated with the worst results in all 
the observed parameters. 
Descriptors: Psychomotor agitation; Psychotic disorders; Antipsychotic 
agents; Emergencies; Tranquilizing agents/adverse effects 
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Resumo
Objetivo: Comparar a eficácia da olanzapina, ziprasidona, haloperidol 
associado ao midazolam, haloperidol associado à prometazina e haloperidol 
isoladamente por via intramuscular como primeira escolha no tratamento de 
pacientes em agitação e agressividade. Método: Cento e cinquenta pacientes 
com agitação psicomotora por transtorno psicótico ou transtorno bipolar foram 
recrutados para estudo duplo-cego e receberam olanzapina, ziprasidona, 
haloperidol associado a  midazolam, haloperidol associado a prometazina 
ou haloperidol isoladamente. Foram aplicadas as escalas Overt Agitation 
Severity Scale, Overt Aggression Scale e Ramsay Sedation Scale no período 
de 12 horas após a primeira aplicação. Resultados: Todas as medicações 
foram capazes de acalmar os pacientes após uma hora da administração. 
Apenas a olanzapina e o haloperidol reduziram a agitação para menos de 
10 pontos e apenas a olanzapina reduziu a agressividade para menos de 
quatro pontos nesse período. Doze horas depois, apenas o haloperidol com 
midazolam apresentou valores altos para a agitação e agressividade, e também 
esteve relacionado com maior proporção de efeitos colaterais. A ziprasidona, 
a olanzapina e o haloperidol apresentaram resultados mais estáveis para o 
controle da agitação e a ziprasidona, haloperidol associado a  prometazina 
e olanzapina para o controle da agressividade. Conclusão: A olanzapina, a 
ziprasidona, o haloperidol associado a  prometazina, o haloperidol associado 
ao midazolam e o  haloperidol isoladamente foram efetivos no controle da 
agitação e da agressividade secundária a transtornos mentais dentro de 12 
horas. Todas as drogas apresentaram vantagens e desvantagens, exceto pela 
associação haloperidol e midazolam que demonstrou os piores resultados em 
todos os parâmetros.
Descritores: Agitação psicomotora; Transtornos psicóticos; Agentes 
antipsicóticos; Emergências; Tranquilizantes/efeitos adversos
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Introduction
Agitated or violent behavior primarily results from serious mental 
illness and substance misuse,1,2 and constitutes approximately 
10% of the use of emergency services.2,3 Because rates of mental 
illness are similar worldwide,2-4 the management of aggressive and 
violent behavior is an important issue and a mental health priority 
in low and middle income countries, where the majority of the 
world’s population live, and particularly in countries with large 
populations2 such as Brazil.
Drugs commonly used to manage agitation and violence in 
emergency situations include antipsychotics, benzodiazepines 
and combinations of antipsychotics and benzodiazepine or 
antipsychotics and promethazine.5,6 More recent strategies include 
longer-acting drugs, such as zuclopenthixol acetate,7 and rapidly 
acting intramuscular formulations of the atypical antipsychotics 
olanzapine8 and ziprasidone.9 Guidelines state that drugs used in 
such situations should calm patients safely and rapidly without 
excessive sedation (rapid tranquilization). However, the guidelines 
differ regarding which drugs to use.4,10 In this context, some of 
the new generation antipsychotics are not only for oral use, but 
can also be used parenterally, which represents an advance in the 
rapid management of acute behavioral alterations. Additionally, 
knowledge regarding antipsychotic profiles in the treatment of 
agitation and aggressive behavior is limited, and few studies have 
compared the effects of different drugs in rapid tranquilization. 
We conducted a double-blind controlled trial to compare the 
effectiveness of intramuscular olanzapine, ziprasidone, haloperidol 
plus promethazine, haloperidol-plus- midazolam and haloperidol 




The method of randomization employed in this clinical trial was 
allocation by permuted blocks. Each drug regimen was assigned 
to blocks of five patients and distributed in this order: olanzapine, 
ziprasidone, haloperidol plus prometazine, haloperidol plus 
midazolam and haloperidol. This assignment was repeated until 
the total number of subjects (150) was reached. 
2. Participants
One hundred fifty subjects who had been admitted to the 
Psychiatric Emergency Room of Santa Casa de São Paulo in 
Brazil were selected. The inclusion criteria were as follows: signs of 
agitation, age between 18 and 50 years, bipolar (maniac or mixed 
episode) or psychotic disorder diagnosis (DSM-IV-TR criteria), 
Overt Agitation Severity Scale Total Score (OASS) equal or greater 
than 20 and an Overt Aggressive Scale (OAS) with four or more 
positive items. The exclusion criteria were as follows: disorders due 
to drug abuse, organic disorder, anxiety or personality disorder 
(DSM-IV-TR criteria), failure to agree to participate in the study, 
incapability of completing all steps and unstable clinical disease. 
Upon entry of each patient into the study, demographic 
information, medical history, characteristics of the current 
symptomatology and psychiatric and family history were obtained. 
In addition, a full physical and neurological examination was 
completed as soon as possible, although only if the patient was 
considered eligible for the study.
All participants provided written informed consent before and 
after participating in this study, which was reviewed and approved 
by the institutional review board. Written consent was obtained 
before admission to the emergency unit by a legal guardian and 
after 12 hours by the patient (when he or she was able to understand 
the information) or by the guardian. This study was conducted 
according to the principles of the Declaration of Helsinki and 
Good Clinical Practice. It was approved by the Institutional 
Review Board (IRB) of Santa Casa de São Paulo (Project CEP 
364/07) and was registered in the Australian New Zealand 
Clinical Trials Registry as number ACTRN12610000033044. 
The international registration is available at http://www.anzctr.
org.au/trial_view.aspx?ID=334977.
3. Study design and assessment instruments
To evaluate inter-rater reproducibility, two raters repeatedly 
applied OASS, OAS and RSS to the patients admitted to the 
emergency room before the study until the intraclass correlation 
coefficient (ICC) was greater than 0.80. After 10 applications, 
the ICC was 0.90.
The study medications were packaged in identical color-coded 
boxes. The first dosage included either 10mg of olanzapine, 20mg 
of ziprasidone, 5mg of haloperidol plus 50mg of prometazine 
or 5mg of haloperidol plus 15mg of midazolam. Dosages were 
chosen based on previous studies.2,10-12 After the initial dose, only 
additional doses of the haloperidol and promethazine combination 
could be used, according to clinician judgment. If a subject needed 
another intervention, he or she was immediately removed from 
the study. 
All subjects were assessed 1 hour, 2 hours, 4 hours, 6 hours and 
12 hours after t he first administration of the medication. Protocol-
defined psychiatric assessments included the OASS, the number 
of positive items on the OAS and the Ramsay Sedation Scale score 
(RSS). No additional medications or side effects were observed.
Patients were assessed by two psychiatrists. The psychiatrists 
were all masked with regard to the patient’s treatment assignment, 
and patients were instructed not to reveal their current treatment 
to the investigators. In an attempt to reduce inter-rater variability, 
all raters were trained to administer the psychometric tools 
according to common standards prior to study enrollment. In 
addition, psychopathology rater training was performed regularly 
throughout the study to establish a high inter-rater reliability. 
Finally, all of the investigators conducted joint interviews before 
the commencement of the study, and joint ratings were made 
throughout the study to check inter-investigator agreement.
The clinical safety of treatment was assessed by spontaneous 
notification and an open-ended inquiry into adverse events as 
well as a full physical examination and measurement of vital signs 
at each visit. Adverse events and drug compliance were carefully 
monitored throughout the study. Patients were withdrawn 
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from the trial if they requested discontinuation, if the physician 
suggested withdrawal because of an adverse event, if the treatment 
showed lack of efficacy or if the patients were uncooperative.
4. Statistical analyses
All 150 participants completed the acute trial. Data were 
analyzed using the Statistical Package for the Social Sciences 15.0 
for Windows.13 A two-tailed statistical significance level was set 
at p < 0.05. Skewness and kurtosis were used as normality tests. 
In this study, numerical values are presented as the mean 
and standard deviation (SD) unless otherwise specified. Group 
comparisons of baseline demographic and clinical characteristics 
were assessed via the one-way analysis of variance (ANOVA) 
when variable was normally-distributted, Kruskal–wallis test 
when variable was not normally-distributted and chi-square test 
for categorical variables. 
The outcome evaluation used mixed-effect analyses of 
covariance (ANCOVAs) with medication (olanzapine, ziprasidone, 
haloperidol plus midazolam, haloperidol plus promethazine and 
haloperidol alone) as a between-groups factor and time (1 hour, 
2 hours, 4 hours, 6 hours and 12 hours) as a within-group factor. 
OASS at time zero, OAS at time zero, the number of additional 
medications and the presence of excessive sedation were fixed 
covariates, and symptom ratings (OASS, OAS and RSS) were 
time-varying covariates. The analyses were based on mean score 
differences between the groups at each time point. Analyses of 
variance with post-hoc Duncan’s tests were calculated to compare 
the mean OASS, OAS and RSS scores between the groups. Effect 
size was evaluated by the mean ratio calculated with OASS and 
OAS after 1, 2, 4, 6 and 12 hours as the numerators, and OASS and 
OAS at time zero as the denominator. The mean ratio represents 
the proportion of score reductions compared to the initial scores. 
The mean of all ratios was used as the parameter representing a 
stable result because lower values represent minor variations, i.e., 
lower rates of recurrence of agitation or aggression within 12 hours. 
Results
A total of 163 patients were screened, and 150 underwent 
randomization and received at least one dose of medication 
(Figure 1). Eighty-eight did not meet the inclusion criteria, and 
five refused to participate.
For the total patient group, the average mean age was 32.1 
(SD = 7.7), 59.5% were men, 60.6% had a psychotic disorder 
and 39.4% had bipolar disorder. At the time of entry into the 
study, the patients had an OASS (mean) of 30.8 (SD = 5.1) and 
an OAS of 10.1 (SD = 2.5). The sociodemographic and clinical 
characteristics of all five treatment groups were similar (Table 1). 
No statistically significant differences with respect to age, gender, 
education, employment and diagnosis were found between the 
four medication groups.
When a patient displayed agitation and/or aggressive behavior 
within 12 hours, additional medication was administered when a 
verbal approach failed. If the behavior was at high risk, mechanical 
restriction was performed. A larger proportion of patients who 
received haloperidol plus midazolam (70%) required mechanical 
restraint between one hour after the first medication and the 
final 12 hours of observation, followed by the groups receiving 
ziprasidone (33%), haloperidol alone (20%), haloperidol plus 
promethazine (17%) and olanzapine (3%) (p < 0.001). The 
haloperidol plus midazolam group had a higher mean value of 
additional medication after first the dosage (1.73; SD = 0.87), 
followed by the haloperidol alone group (1.53; SD = 1.19) and 
the haloperidol plus promethazine group (1.10; SD = 1.03); 
p < 0.001. The groups receiving ziprasidone (0.77; SD = 0.98) 
and olanzapine (0.37; SD = 0.77) had a mean value less than 1, 
which indicates that a higher number of patients did not need 
additional medications.
Side effects were higher in the haloperidol plus midazolam 
(50%), haloperidol alone (38%), and haloperidol plus 
promethazine (33%) groups, but these differences were not 
statistically significant. Excessive sedation was the main side effect 
(70% of all side effects) and was highest in the haloperidol plus 
midazolam group (p < 0.001). Extrapyramidal side effects were 
present in only three patients in the haloperidol plus midazolam 
group, five patients in the haloperidol plus promethazine group 
and five patients in the haloperidol alone group (not statistically 
significant). Hypotension was present in one patient in the 
olanzapine group, six patients in the ziprasidone group, five 
patients in the haloperidol plus midazolam group and three in 
the haloperidol plus promethazine group.
Table 2 describes the treatment outcomes in the five treatment 
groups. The OASS, OAS (number of positive items) and the RSS 
mean total scores were compared at each time point by ANCOVA 
(including time zero for the OASS and OAS) covarying for 
mechanical restriction after the first dosage and the number of 
additional medications. The time×drug interactions, indicating 
differences in the effectiveness among treatments, were significant. 
For more details, see Figure 2.
The OASS mean total scores at the first hour were, in decreasing 
order, 14.6 (SD = 3.4) for the haloperidol plus midazolam group, 
13.0 (SD = 5.3) for the haloperidol plus promethazine group, 
12.6 (SD = 4.3) for the ziprasidone group, 4.9 (SD = 2.1) for the 
haloperidol alone group and 2.9 (SD = 0.9) for the olanzapine 
group (p < 0.001). The OAS total score at the first hour was 
highest for the haloperidol plus promethazine group (8.8; 
SD = 4.6), followed by the haloperidol plus midazolam (5.5; 
SD = 2.9), haloperidol alone (4.3; SD = 1.0), ziprasidone (4.3; SD = 
1.9) and olanzapine groups (3.4; SD = 1.0) (p < 0.001). The RSS at 
the first hour was highest for the haloperidol plus midazolam group 
(3.0; SD = 1.1) and was similar for the other groups (p = 0.016).
In the middle of the acute treatment (second, fourth and sixth 
hours), significant group improvements were observed in all 
groups. Moreover, differences between them were observed only 
for the OASS for all times. Differences in the OAS were present 
only in the second hour, and there were no RSS differences 
between groups.
At the endpoint (twelfth hour), the OASS was highest for the 
haloperidol plus midazolam group (12.6; SD = 2.9), followed by 
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haloperidol plus promethazine = haloperidol plus midazolam). For 
the OAS, ziprasidone had the best results, followed by haloperidol 
plus promethazine, olanzapine, haloperidol alone and haloperidol 
plus midazolam. The Waller-Duncan test demonstrated that 
ziprasidone = haloperidol plus promethazine < olanzapine < 
haloperidol = haloperidol plus midazolam.
Discussion
The intramuscular antipsychotics tested in this research were 
effective in the rapid tranquilization of patients exhibiting agitation 
or violence as a result of mental illness. However, important 
differences were found in the effects of the interventions. 
Consensus guidelines emphasize that calming, rather than over-
sedating, the patient is a key goal in the initial management of agitation 
in the acute setting.14-16 Historically, traditional agents have been used 
as first-line medications for the treatment of acutely agitated patients, 
in part because of the availability of parenteral preparations. However, 
because of the recent introduction of parenteral forms of atypical 
the ziprasione (4.1; SD = 1.0), haloperidol plus promethazine (2.2; 
SD = 0.7), haloperidol (1.4; SD = 0.1) and olanzapine groups (0.5; 
SD = 0.2), (p = 0.001). For OAS, the highest mean total score was 
found in the haloperidol plus midazolam group (4.5; SD = 1.9), and 
the lowest mean value was for the haloperidol plus promethazine group 
(0.8; SD = 0.3). The olanzapine (2.8; SD = 0.5), haloperidol (2.6; 
SD = 0.2) and ziprasidone (2.4; SD = 0.3) OAS means were similar 
(p < 0.001). There were no differences in RSS at the twelfth hour.
To compare effect sizes, we calculated the mean ratios for the 
OASS and OAS between each hour (1, 2, 4, 6 and 12 hours 
after) and time zero. For the OASS, ziprasidone and olanzapine 
produced lower scores, indicating more improvement in agitation 
and stable results. Haloperidol had good results, while haloperidol 
plus promethazine and haloperidol plus midazolam had the worst 
results. According to the Waller-Duncan post-hoc test (5%), 
ziprasidone was similar to olanzapine and haloperidol, and all three 
had lower scores than haloperidol plus midazolam and haloperidol 
plus promethazine (olanzapine = ziprasidone = haloperidol < 
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antipsychotics, such as olanzapine and ziprasidone, these medications 
have been gaining popularity as first-line treatment options because 
of their more favorable side effect profiles.14,17
Haloperidol is a highly potent, widely used neuroleptic that 
may promote adequate levels of tranquilization when administered 
intramuscularly (IM). Acute adverse effects include akathisia, 
dystonic reactions and neuroleptic malignant syndrome.17 Despite 
these adverse effects, which may occur even after a single injection, 
haloperidol is the preferred treatment, is widely available and is 
used in emergency situations.17
Butyrophenones belong to a class of drugs that have been 
available for many years. Haloperidol reaches peak plasma levels 
about 20 minutes after intramuscular administration. The mean 
plasma (terminal elimination) half-life has been determined to be 
20.7 (SD = 4.6) hours, and although excretion begins rapidly, only 
24 to 60% of the ingested radioactive drug is excreted (mainly as 
metabolites in urine, some in feces) by the end of the first week, 
and very small but detectable levels of radioactivity persist in the 
blood and are excreted for several weeks after dosing. About 1% 
of the ingested dose is recovered unchanged in the urine.
Haloperidol alone reduces agitation and psychotic effects, as 
measured via different scales.18 In this study, haloperidol alone 
reduced agitation and aggression at the first hour, similar to 
atypical antipsychotics, and had stable results for agitation control 
but worse results for aggressive behavior control. In clinical 
practice, haloperidol alone has been used because it has fewer 
side effects (especially excessive sedation and hypotension19), but 
this option could be related to additional medication that was 
demand within 12 hours after the first administration. Moreover, 
haloperidol alone is associated with more extrapyramidal side 
effects, such as acute dystonia.4 
However, haloperidol associated with other medications 
can produce superior results.18,20 Possible combinations that 
have been tested include haloperidol paired with lorazepam,21 
thiothixene,20 phenobarbital20 and promethazine.22 Promethazine 
is an antihistamine that is combined with haloperidol in an IM 
injection for the management of acutely disturbed people.23 The 
rationale for this combination lies in the main sedative effects 
of promethazine and its antimuscarinic properties.23 The main 
adverse reactions of promethazine are gastrointestinal disturbances, 
dry mouth and blurred vision. Paradoxical reactions, such as 
central nervous system stimulation and extrapyramidal symptoms, 
have also been reported.23 
In this study, we observed that haloperidol plus promethazine 
had higher scores of OASS and OAS in the first hour than all 
other medications. However, the patients who received this drug 
option likely had more serious behaviors in the early hours. When 
we observed effect size by the mean of all ratios, haloperidol plus 
promethazine had the worst results for agitation control, but 
better results for aggressive behavior control. In addition, the 
group receiving haloperidol plus promethazine had less need 
for additional medication, fewer side effects and less need of 
mechanical restriction than those receiving haloperidol alone and 
haloperidol plus midazolam. 
Huf et al. showed that patients allocated haloperidol plus 
promethazine were more likely to be tranquil or asleep within 20 
minutes than those who received intramuscular haloperidol alone 
and needed fewer additional medications, but no differences were 
found after 20 minutes.11 Haloperidol given without promethazine 
in this situation causes frequent serious adverse effects.24 Compared 
to midazolam used alone, haloperidol plus promethazine was an 
effective means of tranquilization, with over two-thirds of patients 
being tranquil or sedated by 30 minutes. Midazolam was more 
rapid but was associated with oversedation.2,24 Compared with 
lorazepam, more patients were tranquil or sedated within 30 
minutes if given the combination treatment.25 
The combination of IM benzodiazepines and haloperidol 
has historically been the standard of care for acute agitation in 
χ2
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emergency room settings due to the rapid onset of its effects and 
the ability to administer it to uncooperative patients.26 However, 
this approach is associated with several potential drawbacks. 
Benzodiazepines have the potential to cause respiratory depression, 
usually midazolam more so than lorazepam. Thus, the use of this 
group of drugs outside of services fully qualified in observing for 
and managing the consequences of respiratory distress is difficult 
to justify.4,24 Many patients perceive parenteral administration as 
coercive and abusive, and 93% of patients rank oral formulations as 
their preferred treatment option during a behavioral emergency.15 
Midazolam’s half-life is two to three hours with a duration 
of action generally up to 120 minutes. Some adverse effects are 
associated with the IM use of midazolam, including amnesia, 
respiratory depression, paradoxical reactions and confusion.23 
Although many physicians in Brazil use haloperidol plus midazolam 
for agitated patients, before this study, there was no research on the 
efficacy and safety of this combination. In this study, we had the 
worst results with the haloperidol plus midazolam groups. The mean 
ratios for agitation and aggressive behavior within twelve hours were 
higher, and this group had a higher need for mechanical restriction, 
excessive sedation and additional medication. This combination 
also resulted in a greater number of patients who still were not fully 
tranquilized after twelve hours. We believe that the poor results of 
haloperidol plus midazolam were due to two factors: its short half-
life and the paradoxical reaction of midazolam. This last reaction 
was observed in previous reports27-30 and may have been exacerbated 
by the anticholinergic effects of promethazine (haloperidol plus 
promethazine was the standard option for additional medication 
in this study).
One possible alternative to midazolam is lorazepam, which is 
effective for rapid tranquilization.24 Its association with haloperidol 
was safe but had conflicting results when compared with the use 
of lorazepam alone.18,21,31 In addition, intramuscular lorazepam 
is not available in Brazil.
Atypical antipsychotic agents are a newer class of drugs that are 
gaining popularity in the treatment of acutely agitated patients 
because of their more favorable side effects. Atypical antipsychotics 
are as effective as typical antipsychotics and have reduced the 
incidence of extrapyramidal side effects, including akathisia, 
dystonia and tardive dyskinesia.17,32 Of the atypical agents, two 
currently have an IM form available: olanzapine (Zyprexa®) and 
ziprasidone (Geodon®). Both are at least as effective as haloperidol 
at producing rapid tranquilization in acutely agitated patients. 
Peak plasma concentrations of ziprasidone are achieved within 30 
to 45 minutes with a half-life of 2.2 to 3.4 hours after IM injection. 
Similar results were obtained after IM injection of olanzapine with 
a peak plasma concentration achieved within 15 to 30 minutes. 
Atypical antipsychotics may be associated with prolongation 
of the QT interval and sudden cardiac death, and appropriate 
precautions should be taken when administering the drug.17,33
Although some trials have provided limited evidence for a 
superior speed of onset34,35 or degree of response,32,34,36 other 
studies have demonstrated similar results between first-generation 
and second-generation antipsychotics (SGA).10,37 Moreover, 
other studies have not consistently demonstrated the superior 
efficacy of SGA compared to haloperidol alone.35,38-40 Our 
results demonstrated that olanzapine required fewer additional 
medications, which was different from the results of the TREC 
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study.4 Some clinical trials among patients with acute agitation 
associated with schizophrenia have demonstrated that the IM 
formulations of atypical antipsychotics provide similar efficacy to 
those of conventional antipsychotics, albeit without the associated 
high incidence of extra-pyramidal side effects (EPS).14,37,41-43
Short-term treatment with atypical antipsychotics offers 
improvements over haloperidol. In a seven-day randomized, 
open-label multicenter international study, the efficacy of IM 
ziprasidone (10mg initially, then 5 to 20mg every 4 to 6 hours, 
up to a maximum daily dose of 80mg; n = 90) was compared 
with that of IM haloperidol (2.5 to 10mg, up to a maximum 
daily dose of 40mg; n = 42) in the treatment of hospitalized 
patients with acute psychotic agitation.9 Treatment with IM 
ziprasidone achieved significantly greater mean reductions from 
the baseline in psychotic symptoms and agitation compared with 
IM haloperidol. Furthermore, the mean percentage improvement 
in efficacy variables with IM ziprasidone was at least double 
that of IM haloperidol. Adverse events, and especially EPS, 
were reported less frequently with IM ziprasidone than with IM 
haloperidol.9 In a similar short-term study, IM olanzapine was 
associated with significant reductions in agitation 15 minutes, 30 
minutes and 45 minutes after the first injection, as compared to 
IM haloperidol. This result indicates a more rapid onset of action. 
In this and two other short-term studies,34 IM olanzapine and IM 
haloperidol showed similar efficacy from two hours after the first 
injection. Another study demonstrated that olanzapine had similar 
proportions of people being tranquil or asleep at 15 minutes than 
haloperidol plus promethazine; however, contrary to our results, 
more people given olanzapine required additional drugs over four 
hours than those given haloperidol plus promethazine.10
In settings where medical resources are scarce or clinics are 
busy, the longer duration of action for olanzapine, ziprasidone, 
haloperidol plus promethazine and haloperidol alone exposes 
people to dangerous behavior for shorter periods of time, 
provides fewer occasions for doctors to be called in and results 
in a reduced need for additional drugs over the first few hours. 
In addition, the cost of drugs poses one of the biggest problems 
for these interventions. Haloperidol and promethazine are 
both on the World Health Organization’s list of essential 
drugs.4 In combination, these drugs cost nearly a third less 
than injectable olanzapine. If the costs of the additional drugs 
used and the utilization of additional resources were totaled, 
the difference is likely to favor haloperidol plus promethazine 
or haloperidol alone.
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Limitations
The present study suffers from a number of limitations that 
must be taken into account in the interpretation and generalization 
of these results. First, the setting was a psychiatric emergency 
service of a large metropolitan area. This means that psychiatrists 
in the emergency room are often under pressure and at high risk 
of excessively rapid evaluations and dispositions. We tried to 
minimize this factor by using the inter-rater reliability of the raters. 
Second, we only included in the study patients who gave informed 
consent to exclude those who were more severely ill and who were 
compulsorily admitted. This is not an unusual problem in clinical 
research, but it is one that could impair the generalizability of the 
results. Third, our sample size may not have been large enough 
to detect small differences, but our objective was to compare 
several options of rapid tranquilization used by physicians in 
Brazil. Fourth, we evaluated only patients with psychotic or manic 
episodes because another diagnosis could require the adjustment 
of the drug regimen, such as intoxication, delirium and dementia.
Moreover, there are potential limitations of OASS and OAS. 
OASS and OAS evaluate only agitation and aggression conditions. 
They are not diagnosis scales and are not appropriate for observing 
psychotic or mood symptoms. However, they are indicated for 
acute situations. In addition, these scales require training and 
inter-rater reliability because they can be easily exaggerated or 
minimized by the person completing them. Like all questionnaires, 
the method by which the instrument is administered can have an 
effect on the final score. Finally, RSS relies on patient auditory 
and visual acuity and is not suitable for patients with severe 
impairments.
Conclusion
Olanzapine, ziprasidone, haloperidol plus promethazine, 
haloperidol plus midazolam and haloperidol alone were effective 
in controlling agitation and violent behavior resulting from 
mental illness by producing tranquilization over 12 hours. Patients 
given olanzapine had better results for agitation control, a lower 
percentage of excessive sedation and less need of mechanical 
restriction. Patients given ziprasidone had better results for 
controlling aggressive behavior, followed by haloperidol plus 
promethazine. All the drug combinations had advantages and 
disadvantages, and the combination of haloperidol plus midazolam 
showed the worst results in all the parameters observed. Aside 
from their higher cost, atypical antipsychotics may be helpful and 
might be an option in emergencies.
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